ArticleBMC cardiovascular disorders2025
Blood urea nitrogen to left ventricular ejection fraction ratio is a predictor of in-hospital outcomes in ST-elevation myocardial infarction patients: a case control study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prehospital Risk Stratification Using Unsupervised Machine Learning in STEMI.European journal of clinical investigation · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe in-hospital mortality of ST-elevation myocardial infarction (STEMI) remains as high as 4–12%. Heart and kidney are closely linked, and both renal and cardiac function have been confirmed to be associated with the prognosis in patients with STEMI. This study intends to evaluate the prognostic value of blood urea nitrogen (BUN) to left ventricular ejection fraction (LVEF) ratio (BLR) in STEMI patients.
methodsFrom January 2015 to January 2023, 2435 consecutive STEMI patients were enrolled. The primary endpoint was in-hospital all-cause mortality and the second endpoint was major adverse cardiovascular events (MACE) including cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction. The predictive value of BLR was compared with BUN, LVEF, traditional markers and scores (GRACE score and TIMI score) by receiver operating characteristic (ROC) curves, the area under the curve (AUC) were compared by DeLong test. Then patients were divided into two groups based on the cut-off value of BLR determined by Youden index and compared the in-hospital mortality and MACE. The association between BLR and endpoints was investigated by Cox regression.
resultsTotally 2435 patients were included in our study, among which 90 (3.70%) patients died and 110 (4.52%) MACEs were collected. The non-survivors had significantly higher BUN level and lower LVEF value. The AUCs and DeLong test showed that the predictive value of BLR was significantly higher than BUN, LVEF, creatinine, N-terminal pro-brain natriuretic peptide (NT-proBNP), and troponin I but was comparable to GRACE score and TIMI scores. The optimal cut-off value of BLR was 12.54 with a sensitivity of 75.6% and a specificity of 67.6%. The in-hospital mortality and MACE was significantly higher in high BLR group (8.23% vs. 1.37% for in-hospital mortality and 9.44% vs. 1.99% for in-hospital MACE, all p < 0.001). After multivariable adjustment, BLR ≥ 12.54 was still independently associated with higher in-hospital mortality (HR = 2.464, 95%CI 1.448, 4.192, p < 0.001) and MACE (HR = 1.850, 95%CI 1.175, 2.911, p = 0.008).
conclusionBLR is an important prognostic index to identify patients at high risk of in-hospital prognosis in STEMI patients and the prognostic value was comparable to or even higher than traditional prognostic scores.
trial registrationChiCTR1900028516 ( http//www.chictr.org.cn ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.